Compass Pathways Leads Psychedelic Drug Stocks on Trump Order

 StocksRunner
 
  StocksRunner
 
Follow  Message
 
 
 
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
 

•  20 Apr 2026
 

$CMPS $ATAI $GHRS $CYBN $ENVB Psychedelic-focused biotech stocks surged after U.S. President Donald Trump signed a new executive order aimed at accelerating the development and approval of mental health treatments. The policy directive targets the biotechnology sector, positioning companies against emerging competitors while increasing relevance to broader healthcare indices, with a regulatory catalyst driving institutional flows and multiple expansion expectations.

The order, signed Saturday, instructs the U.S. Food and Drug Administration to expedite review processes for psychedelic drugs, particularly those already granted breakthrough therapy designation. Approval timelines could be reduced from approximately 6-10 months to a matter of weeks to a few months through accelerated review vouchers. The FDA is expected to issue national priority vouchers for advanced development programs, with Chairman Marty Makary indicating that some decisions could be reached as early as this summer. This marks a structural shift in regulatory posture, compressing timelines and reducing friction in the approval pipeline.

Market reaction was immediate. $ATAI gained approximately 25%, $CMPS surged more than 55%, and $GHRS, $CYBN, and $ENVB posted double-digit advances, while a sector-focused ETF rose around 11%. $CMPS is leading the move on the back of advanced clinical progress, reinforcing earnings momentum narratives and attracting incremental capital as investors reposition around regulatory clarity. The move reflects a repricing of regulatory risk and a shift in positioning as capital rotates into early-stage therapeutic platforms.

The executive order explicitly references psychedelic compounds currently under research, including ibogaine, psilocybin, MDMA, and LSD. These substances remain federally illegal and classified as having no accepted medical use, yet are being evaluated as potential treatments for depression, PTSD, and addiction. Ibogaine, derived from an African plant, is under investigation for opioid addiction treatment but carries known risks, including potential cardiac effects, limiting its use to clinical trials.

In parallel with regulatory acceleration, the order includes an allocation of approximately $50 million in federal funding for ibogaine research, marking the first targeted budgetary support for psychedelic therapeutics. Analysts view the move as formal validation of the sector importance, materially reducing regulatory overhang, though scientific challenges persist. Clinical trials face structural limitations, as patients can often identify whether they received active compounds, complicating placebo-controlled study design and impacting data integrity.

Regulatory delays have already occurred, including the FDA 2024 rejection of an MDMA-based PTSD treatment due to data quality and adverse event reporting concerns. Despite this, $CMPS reported positive results earlier this year from two advanced-stage trials of its psilocybin-based treatment for treatment-resistant depression, a segment with limited effective options. The company is developing a synthetic psilocybin therapy targeting mental health disorders, reinforcing its positioning within a high-unmet-need market.

$ATAI is advancing a nasal spray-based treatment targeting the same patient population, with a Phase 3 trial expected later this year, a critical milestone in the approval pathway. Large pharmaceutical companies are beginning to show interest, with recent acquisitions and partnerships signaling early positioning ahead of potential regulatory maturation. The policy shift is also supported by relatively broad political backing, with bipartisan willingness to expand access to psychedelic treatments, particularly for patients lacking effective alternatives.

Watch for accelerated FDA decisions and priority voucher allocations as the next trigger.

View all market intelligence